Arda Therapeutics

targeted cell depletion, single-cell data, biologics

clearingbiologic

ardatx.com·San Carlos, California, United States·Series A·$43M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-Y0XT

Projects

Immunological and Inflammatory Disease Cell-Depletion Programs

undisclosed

drug program · medium · Wed Oct 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop targeted cell depletion therapies for immunological and inflammatory diseases, with possible broader applicability to fibrotic, autoimmune, and metabolic disorders.

Targeted biologics designed from single-cell and machine-learning-derived pathogenic cell markers to selectively eliminate disease-driving cells.

Initial therapeutic focus disclosed alongside the Series A financing announcement.

Targeted Cell Depletion Therapy Platform

undisclosed

platform · high · Wed Oct 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Identify and selectively eliminate pathogenic cell populations that drive chronic diseases, rather than modulating the proteins those cells produce.

Uses single-cell data and custom machine learning methods to identify disease-driving cell populations and cell-surface markers, then develops targeted biologics to deplete harmful cells.

Arda announced a $43 million Series A financing to advance targeted cell depletion therapies.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence